Liver transplant patients gain same benefits from CellCept® as kidney transplant patients
25th May 2005, Basel, Switzerland – New data reported in over 90 abstracts presented at the American Transplant Congress in Seattle show that liver transplant patients taking the immunosuppressant CellCept® are gaining the same positive benefits already demonstrated in kidney transplant patients. This is good news for patients as the demand for liver transplants is increasing, with many of the cases directly resulting from chronic hepatitis C virus (HCV) infection.
Benefits seen with CellCept include:
- Reduced risk of acute rejection, especially in patients infected with HCV
- graft rejection is of particularly high risk in HCV patients and is associated with increased morbidity and decreased patient and graft survival (Abstract 928)
- Safe and effective steroid-free regimens for HCV patients
- steroids are known to have a negative impact on the progression of HCV, which can result in liver fibrosis (Abstract 475)
- Optimal kidney function
- CellCept taken with a low dose of tacrolimus showed a trend towards improved kidney function (Abstract 1240). CellCept is proven to promote excellent kidney function early after kidney transplantation in renal patients taking tacrolimus(1)
- Less liver fibrosis
- recipients taking CellCept-based regimens showed a significant reduction in the inflammation and structural changes that can lead to liver failure (Abstract 1446)
- No increased risk of malignancy
- the addition of CellCept to maintenance immunosuppression that includes tacrolimus and corticosteroids did not increase the risk of death due to malignant complications (Abstract 930). This confirms previous data as seen in kidney transplant recipients(2)
"It's really exciting to see liver transplant recipients benefiting from CellCept in the same way as kidney transplant patients. Our aim is to find the most effective, least toxic immunosuppressive regimen for our patients so we can ensure that they enjoy a long, healthy and active life post transplant," said Dr. Bjorn Nashan, Dalhousie University, Halifax, NS, Canada. "CellCept's unrivalled 10 years of data show the impact that effective, low toxic regimens have had on improving long-term outcomes and patient survival."
Liver transplantation has become a widely accepted and effective therapy for a number of irreversible acute and chronic liver diseases. These can include cancer of the liver and bile ducts, viral hepatitis as well as liver cirrhosis. One-year survival has reached 90% and three-year survival is 80%.(3)
CellCept, with over 10 years of evidence base and clinical experience, is the only mycophenolic acid (MPA) derivative indicated for liver, kidney and heart transplant patients and is currently prescribed to more than half the liver transplanted population.(4) CellCept is also the only MPA derivative with proven survival benefits for liver, kidney and heart transplant recipients.(5,6,7)
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.